Skip to main content

Table 1 Baseline demographic and clinical characteristics of study and validation groups

From: Gene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failure

Characteristics Study group (n = 111) Validation group (n = 41) P value
Men 86 (77.5%) 31 (75.6%) 0.83
Women 25 (22.5%) 10 (24.4%) 0.83
Age (years) 58.8 ± 10.4 61 ± 10.6 0.277
BMI (kg/m2) 28.1 ± 4.7 28.9 ± 5.1 0.517
Hypertension 62 (55.9%) 28 (71.8%) 0.09
Diabetes 26 (23.4%) 6 (15.4%) 0.367
Previous MI 8 (7.2%) 3 (7.7%) 1
Smoking 54 (48.6%) 20 (51.3%) 0.853
Hypercholesterolemia 60 (54.1%) 34 (87.2%) <0.001
AMI 54 (51.4%) 17 (43.6%) 0.456
Previous revascularization 3 (2.7%) 2 (5.1%) 0.605
Non-coronary atherosclerosis 6 (5.4%) 3 (7.7%) 0.697
NT-proBNP (pg/mL) 1,641.4 ± 3,675.3 2,913.3 ± 6,975.7 0.559
LVEF (%) 49.3 ± 8.6 42.1 ± 8.3 <0.001
Medicationsa
Aspirin 105 (100%) 39 (100%) NA
Clopidogrel 104 (99%) 39 (100%) 1
Beta blockers 104 (99%) 38 (97.4%) 0.47
ACE inhibitors 100 (95.2%) 39 (100%) 0.324
Statins 103 (98.1%) 39 (100%) 1
Diuretics 21 (20%) 14 (35.9%) 0.079
  1. aData were only available for n = 105 patients from the study group and n = 39 from validation group; these numbers were used to calculate percentages.
  2. Data at admission.
  3. Data are presented as mean value ± standard deviation or number or percentage of patients. P value <0.05 was considered significant.
  4. ACE, angiotensin-converting enzyme; AMI, anterior myocardial infarction; BMI, body mass index; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NA, not applicable; NT-proBNP, N-terminal pro-brain natriuretic peptide.